BRIEF-Pfizer And Innovent Biologics Enter Global Strategic Collaboration To Accelerate Development Of Innovative Oncology Medicines

Pfizer Inc.

Pfizer Inc.

PFE

0.00

May 28 (Reuters) - PfizerPFE.N:

  • PFIZER AND INNOVENT BIOLOGICS ENTER GLOBAL STRATEGIC COLLABORATION TO ACCELERATE DEVELOPMENT OF INNOVATIVE ONCOLOGY MEDICINES

  • PFIZER - AND INNOVENT ENTER GLOBAL LICENSING AND COLLABORATION FOR 12 CANCER MEDICINES

  • PFIZER - TO RECEIVE EXCLUSIVE GLOBAL LICENSE FOR FOUR PROGRAMS

  • PFIZER - INNOVENT TO RECEIVE $650 MILLION UPFRONT AND UP TO $9.85 BILLION IN MILESTONES

  • PFIZER - INNOVENT TO RECEIVE UP TO DOUBLE-DIGIT ROYALTIES ON LICENSED PRODUCT SALES

  • PFIZER: WILL RECEIVE AN EXCLUSIVE LICENSE OUTSIDE GREATER CHINA FOR FOUR PROGRAMS, AND WILL BE RESPONSIBLE FOR MAJORITY OF DEVELOPMENT COSTS

Source text: ID:nBw4f5pFHa

Further company coverage: 1801.HK


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.